Follow-up examinations of @entity1 might detect local @entity5 recurrences at a curable stage, which is more difficult for @entity3 ( @entity3 ). Recently, elevated Cyfra 21-1 serum levels (CySL) could be shown not only to correlate with @entity5 size but also with development of @entity3 . We focussed on the CySL of 476 @entity213 @entity1 as a first step. At first time diagnosis, besides regular staging procedures, these @entity1 were screened for CySL higher than 3.3 ng/ml. Seventeen out of 476 (3.9%) @entity1 showed @entity3 . Seventeen out of 19 @entity1 (89.5%) presented elevated CySL: A further 830 @entity1 with @entity213 were tested for changes in CySL in the course of disease (cut-off value 3.3 ng/ml). Seventy-one out of 830 @entity1 (8.6%) showed elevated CySL. @entity5 growth was found in 50 out of 71 @entity1 (70.4%). In 54% of these @entity1 (27 out of 50) @entity3 were detected. Routine screening for CySL can lead to timely detection of @entity3 in @entity213 , despite its fairly low sensitivity.

Cyfra 21-1 in diagnosis of XXXX of head and neck carcinoma.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'HNSCC-tumor', 'Tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['DM', 'distant metastases']
@entity3 :: (MESH:D009362,Disease) :: ['distant metastases']
